Oric Pharmaceuticals (4TZ) Drug Pipeline

1 Followers

Docetaxel, Enzalutamide, Darolutamide, Rinzimetostat, Taxotere, Oric-944

Metastatic Castration Resistant Prostate Cancer

Phase III

Recruiting

A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)

Jun 18, 2026

―

Oric-114 Dose 1 + Amivantamab, Oric-114 Dose 2 + Amivantamab, Oric-114 Dose 3 + Amivantamab

Solid Tumors, Nsclc, Egfr Exon 20 Insertion Mutations, Egfr-Mutated Nsclc

Phase I

Recruiting

ORIC-114 in Combination with Subcutaneous Amivantamab in Patients with EGFR Exon20 Insertion Mutant NSCLC

Feb 03, 2025

Oric-944, Abiraterone Acetate 250 Mg Or 500 Mg Tablets, Apalutamide 60 Mg Or 240 Mg Tablets, Darolutamide 300 Mg Tablets, Enzalutamide 40 Mg Capsules Or 40 Mg And 80 Mg Tablets

Metastatic Prostate Cancer

Phase I

Recruiting

Study of ORIC-944 in Patients With Metastatic Prostate Cancer

Jun 07, 2022

Chemotherapy Drug, Oric-114

Solid Tumors

Phase I/II

Recruiting

Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

Mar 24, 2022

Oric-533

Relapsed Or Refractory Multiple Myeloma

Phase I

Completed

Study of ORIC-533 in Relapsed or Refractory Multiple Myeloma

Feb 02, 2022

―

FAQ

What are the FDA phases for drug approval?

The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness

What is a clinical trial?

A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.

What drugs does Oric Pharmaceuticals (4TZ) have in its pipeline

4TZ is currently developing the following drugs: Docetaxel, Enzalutamide, Darolutamide, Rinzimetostat, Taxotere, Oric-944, Oric-114 Dose 1 + Amivantamab, Oric-114 Dose 2 + Amivantamab, Oric-114 Dose 3 + Amivantamab, Oric-944, Abiraterone Acetate 250 Mg Or 500 Mg Tablets, Apalutamide 60 Mg Or 240 Mg Tablets, Darolutamide 300 Mg Tablets, Enzalutamide 40 Mg Capsules Or 40 Mg And 80 Mg Tablets. These drug candidates are in various stages of clinical development as the company works toward FDA approval.